Ustun, C. Et Al. 2002. In vivo use of all-trans retinoic acid prior to induction chemotherapy improves complete remission rate and increases rhodamine 123 uptake in patients with de novo acute myeloid leukemia. MEDICAL ONCOLOGY , vol.19, no.1 , 59-67.

Ustun, C., BEKSAÇ, M., Dalva, K., Koc, H., Konuk, N., Ilhan, O., ... Ozcan, M.(2002). In vivo use of all-trans retinoic acid prior to induction chemotherapy improves complete remission rate and increases rhodamine 123 uptake in patients with de novo acute myeloid leukemia. MEDICAL ONCOLOGY , vol.19, no.1, 59-67.

Ustun, C Et Al. "In vivo use of all-trans retinoic acid prior to induction chemotherapy improves complete remission rate and increases rhodamine 123 uptake in patients with de novo acute myeloid leukemia," MEDICAL ONCOLOGY , vol.19, no.1, 59-67, 2002

Ustun, C Et Al. "In vivo use of all-trans retinoic acid prior to induction chemotherapy improves complete remission rate and increases rhodamine 123 uptake in patients with de novo acute myeloid leukemia." MEDICAL ONCOLOGY , vol.19, no.1, pp.59-67, 2002

Ustun, C. Et Al. (2002) . "In vivo use of all-trans retinoic acid prior to induction chemotherapy improves complete remission rate and increases rhodamine 123 uptake in patients with de novo acute myeloid leukemia." MEDICAL ONCOLOGY , vol.19, no.1, pp.59-67.

@article{article, author={C Ustun Et Al. }, title={In vivo use of all-trans retinoic acid prior to induction chemotherapy improves complete remission rate and increases rhodamine 123 uptake in patients with de novo acute myeloid leukemia}, journal={MEDICAL ONCOLOGY}, year=2002, pages={59-67} }